[go: up one dir, main page]

SE0303491D0 - New use VI - Google Patents

New use VI

Info

Publication number
SE0303491D0
SE0303491D0 SE0303491A SE0303491A SE0303491D0 SE 0303491 D0 SE0303491 D0 SE 0303491D0 SE 0303491 A SE0303491 A SE 0303491A SE 0303491 A SE0303491 A SE 0303491A SE 0303491 D0 SE0303491 D0 SE 0303491D0
Authority
SE
Sweden
Prior art keywords
new use
compound
formula
treatment
regurgitation
Prior art date
Application number
SE0303491A
Other languages
Swedish (sv)
Inventor
Anders Lehmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0303491A priority Critical patent/SE0303491D0/en
Publication of SE0303491D0 publication Critical patent/SE0303491D0/en
Priority to PCT/SE2004/001876 priority patent/WO2005058326A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of a compound of formula (I) for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of a compound of formula I for the treatment of gastro-esophageal reflux disease, as well as for the treatment of regurgitation.
SE0303491A 2003-12-19 2003-12-19 New use VI SE0303491D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0303491A SE0303491D0 (en) 2003-12-19 2003-12-19 New use VI
PCT/SE2004/001876 WO2005058326A1 (en) 2003-12-19 2004-12-15 USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0303491A SE0303491D0 (en) 2003-12-19 2003-12-19 New use VI

Publications (1)

Publication Number Publication Date
SE0303491D0 true SE0303491D0 (en) 2003-12-19

Family

ID=30768810

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0303491A SE0303491D0 (en) 2003-12-19 2003-12-19 New use VI

Country Status (2)

Country Link
SE (1) SE0303491D0 (en)
WO (1) WO2005058326A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
CN1575177A (en) * 2000-12-11 2005-02-02 图拉里克公司 Cxcr3 antagonists
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
JP2006512315A (en) * 2002-11-04 2006-04-13 エヌピーエス ファーマスーティカルズ インコーポレイテッド Quinazolinone compounds as calcilytics

Also Published As

Publication number Publication date
WO2005058326A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2005077373A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
CY1107954T1 (en) USE OF MGLUR5 COMPETITORS FOR GERD TREATMENT
EA200870117A1 (en) AZAINDOL INHIBITORS AURORA-KINAZ
EA200600351A1 (en) NEW CONNECTIONS OWNED WITH INHIBITING ACTIVITY WITH RESPECT TO SODI-DEPENDENT TRANSPORT
ATE491703T1 (en) PHTHALAZINONE DERIVATIVES
EA201000050A1 (en) SUBSTITUTED BICYCLOPLASTIC COMPOUNDS
DE602006016313D1 (en) BIPHENYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS C
NO20080942L (en) Amino-5- [4- (difluoromethoxy) phenyl] -5-phenylimidazolone compounds as inhibitors of beta-secretase (BACE)
EA200900934A1 (en) NEW HETEROCYCLIC INHIBITORS NF-κB
ATE449099T1 (en) DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS
EA200801596A1 (en) NEW 11-BETA-HYDROXYANDROST-4-EN-3-ONE
EA200601358A1 (en) NEW CHEMAZ INHIBITORS
NO20070606L (en) Inhibitors of IAP
ECSP099091A (en) CINAMIDE COMPOUND PROFARMACO
BR0207302A (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
TW200635585A (en) Monocyclic substituted methanones
EA201000881A1 (en) Pyridylmethyl-sulfonamide compounds
EA200600330A1 (en) SUBSTITUTED IMIDAZOPIRIMIDINES FOR PREVENTION AND TREATMENT OF CANCER
SE0401653D0 (en) New compounds
EA200401470A1 (en) DERIVATIVES OF PIPERAZINYLACYLIPIPERIDINE, THEIR RECEIVING AND THEIR THERAPEUTIC APPLICATION
EA200601295A1 (en) 1,3-DIOXANE DERIVATIVES AND THEIR ANALOGUES APPLICABLE FOR THE TREATMENT I.A. OBESITY AND DIABETES
EA200701779A1 (en) DERIVATIVES (1,5-DIPHENYL-1N-PYRAZOL-3-IL) OXADIAZOLE, THEIR RECEIVING AND THEIR USE IN THERAPY
NZ597857A (en) Method and composition for treating mucosal disorders
EA200700997A1 (en) 2,5- and 2,6-DESIGNATED BENZAZOL ANALOGUES, USEFUL AS A PROTEINKINAZ INHIBITOR